Opening of United States East Coast Headquarters

RNS Number : 4380F

Creo Medical Group PLC

16 July 2021

 

Creo Medical Group plc

("Creo" or the "Company")

Opening of United States, East Coast Headquarters  

Connecticut site features a learning centre and fully equipped training laboratory to provide on-site immersive, didactic ex-vivo, training sessions supporting Creo's education led commercialisation strategy

Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of surgical endoscopy, announces that it has opened its United States headquarters at the Summit, Danbury, Connecticut, USA.

The space is designed to support Creo's global growth and focus in the key United States market and features a learning centre and a fully equipped laboratory for clinical development and training purposes which will support Creo's education led commercialisation strategy and enable healthcare providers to participate in immersive, didactic ex-vivo training sessions.  United States customer service, finance, product logistics, distribution and other day-to-day functions will also be based in the Danbury, Connecticut, office.  Located, northeast of New York city, the office's proximity to international airports provides convenient access for visiting clinicians and members of staff.

Over the past 18 months, Creo has established a direct commercial team in the United States, led by experienced and successful leaders in market development. The Company also has a US Director of Clinical Education, assisted by Clinical Support Specialists, responsible for ensuring safe and effective use of our product platform and devices.

Creo's CROMA Energy Generator platform is in place at multiple academic institutions across the United States, with key opinion leaders trained through Creo's Clinical Education Programme. These centres have treated our first patients in the United States and have been identified as "Centres of Excellence for the operation of our Clinical Education Programme." They will be key training sites to educate the second wave of United States clinical users. We intend to increase the number of United States installations and training centres to support the scaling of our presence in the United States. 

Craig Gulliford, Chief Executive Officer of Creo, said: " We are delighted and proud to have opened our first United States facility, illustrating our commitment to growth and our focus on the key United States Market. These new premises will provide an excellent working environment for our United States team and a platform to attract further talent in this key region of the United States market."

David Woods, Chief Commercial Officer of Creo, commented: " Since my appointment in August last year, I have been busy assembling an experienced team to help capitalise on our continued evolution and expansion as a leading medical device Company. The opening of this clinical training and commercial support facility in the United States represents the next phase in our planned and sustained development and further illustrates our growth and focus in the United States region, which gives even greater access to another important market ."

Enquires:

Creo Medical Group plc	investors.creomedical.com
Richard Rees (CFO)	[phone]
Cenkos Securities plc	[phone]
Stephen Keys / Camilla Hume (NOMAD)
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus / Lianne Cawthorne	Mob: [phone]

About Creo Medical  

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy.  The Company's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy.  Creo has developed CROMA, an Advanced Energy Platform powered by Kamaptive™ full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive™ is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue . Kamaptive™ technology provides clinicians with increased flexibility, precision and controlled surgical solutions.  

The Company's strategy is to bring its CROMA Advanced Energy Platform powered by Kamaptive™ technology to market, enabling a wide range of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs.  The CROMA Advanced Energy Platform will be developed further for bronchoscopy and laparoscopy procedures.  The Company believes its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment.  

For more information about Creo Medical please see our website, investors.creomedical.com  

 

END

 

 

MSCGPURCMUPGPGA